南京医科大学硕士研究生导师,博士后合作导师。解放军东部战区总医院病理科主任

主持国家自然科学基金3项，江苏省自然科学基金1项

发表论文100余篇1: Wang XT,Xia QY, Ye SB,et al.RNA sequencing of Xp11 translocation-associated cancers reveals novel gene fusions and distinctive clinicopathologic correlations,Mod Pathol.2018.[Epub ahead of print]IF 6.655

2: Xia QY,Wang XT,Zhan XM, et al. Xp11 Translocation Renal Cell Carcinomas (RCCs) With RBM10-TFE3 Gene Fusion Demonstrating Melanotic Features and Overlapping Morphology With t(6;11) RCC: Interest and Diagnostic Pitfall in Detecting a Paracentric Inversion of TFE3.Am J Surg Pathol.2017 May;41(5):663-676. IF5.878

3:Xia QY,Wang Z, Chen N,et al. Xp11.2 translocation renal cell carcinoma with NONO-TFE3 gene fusion: morphology, prognosis, and potential pitfall in detecting TFE3 gene rearrangement.Mod Pathol.2017 Mar;30(3):416-426.IF 6.655

4：Xia QY, Wang XT, Ye SB, Wang X, Li R, Shi SS, Fang R, Zhang RS, Ma HH, Lu ZF, Shen Q, Bao W, Zhou XJ, Rao Q. Novel gene fusion of PRCC-MITF defines a new member of MiT family translocation renal cell carcinoma: clinicopathological analysis and detection of the gene fusion by RNA sequencing and FISH. Histopathology. 2018 Apr;72(5):786-794. IF 3.2

5:Wang XT, Xia QY, Ni H, Ye SB, Li R, Wang X, Shi SS, Zhou XJ, Rao Q. SFPQ/PSF-TFE3 Renal Cell Carcinoma (RCC): A Clinicopathologic Study Emphasizing Extended Morphology and Reviewing the Differences between SFPQ-TFE3 RCC and the Corresponding Mesenchymal Neoplasm despite an Identical Gene Fusion. Hum Pathol. 2017 May;63:190-200. IF 3.2

6:Xia QY, Zhan XM, Fan XS, Ye SB, Shi SS, Li R, Wei X, Wang X, Ma HH, Lu ZF, Zhou XJ, Rao Q.BRM/SMARCA2-negative clear cell renal cell carcinoma is associated with a high percentage of BRM somatic mutations, deletions and promoter methylation. Histopathology.2017 Apr;70(5):711-721. IF 3.2

7:Ni H, Zhang XP, Wang XT, Xia QY, Lv JH, Wang X, Shi SS, Li R, Zhou XJ,Rao Q. Extended immunologic and genetic lineage of mammary analogue secretory carcinoma of salivary glands. Hum Pathol. 2016 Dec;58:97-104. IF 3.2

8:Rao Q, Xia QY, Cheng L, Zhou XJ. Molecular genetics and immunohistochemistry characterization of uncommon and recently described renal cell carcinomas. Chin J Cancer Res. 2016 Feb;28(1):29-49. Review. IF 3.2

9:Wang XT, Xia QY, Ni H, Wang ZY, Ye SB, Li R, Wang X, Lv JH, Shi SS, Ma HH, Lu ZF, Shen Q, Zhou XJ, Rao Q. Xp11 neoplasm with melanocytic differentiation of the prostate harbouring the novel NONO-TFE3 gene fusion: report of a unique case expanding the gene fusion spectrum. Histopathology. 2016 Sep;69(3):450-8.IF 3.2

10:Rao Q, Shen Q, Xia QY, et al. PSF/SFPQ Is a Very Common Gene Fusion Partner in TFE3 Rearrangement-associated Perivascular Epithelioid Cell Tumors (PEComas) and Melanotic Xp11 Translocation Renal Cancers: Clinicopathologic, Immunohistochemical, and Molecular Characteristics Suggesting Classification as a Distinct Entity. Am J Surg Pathol. 2015 Sep;39(9):1181-96. IF5.878

11: Rao Q, Williamson SR, Zhang S, et al. TFE3 break-apart FISH has a higher sensitivity for Xp11.2 translocation-associated renal cell carcinoma compared with TFE3 or cathepsin K immunohistochemical staining alone: expanding the morphologic spectrum. Am J Surg Pathol. 2013 Jun;37(6):804-15. IF5.878

12: Rao Q, Liu B, Cheng L, et al. Renal cell carcinomas with t(6;11)(p21;q12): A clinicopathologic study emphasizing unusual morphology, novel alpha-TFEB gene fusion point, immunobiomarkers, and ultrastructural features, as well as detection of the gene fusion by fluorescence in situ hybridization. Am J Surg Pathol. 2012 Sep;36(9):1327-38. IF5.878

13: Rao Q, Williamson SR, Lopez-Beltran A, et al. Distinguishing primary adenocarcinoma of the urinary bladder from secondary involvement by colorectal adenocarcinoma: extended immunohistochemical profiles emphasizing novel markers. Mod Pathol. 2013 May;26(5):725-32. IF 6.655

14: Rao Q, Xia QY, Wang ZY, et al. Frequent co-inactivation of the SWI/SNF subunits SMARCB1, SMARCA2 and PBRM1 in malignant rhabdoid tumours. Histopathology. 2015 Jul;67(1):121-9. IF 3.2

15: Rao Q, Cheng L, Xia QY, et al. Cathepsin K expression in a wide spectrum of perivascular epithelioid cell neoplasms (PEComas): a clinicopathological study emphasizing extrarenal PEComas. Histopathology. 2013 Mar;62(4):642-50. IF 3.2

申请并获得国家发明专利授权5项（1）专利名称：一种用于诊断Xp11.2易位性肾癌的探针组合及其应用；专利号：ZL 201110440213.2（第一发明人：饶秋）

（2）专利名称：一种用于诊断Xp11.2 易位性血管周上皮样细胞肿瘤的探针组合及其应用；专利号：2014104110230.5 （第一发明人：饶秋）；

（3）专利名称：一种MiT 家族易位性肾细胞癌的新融合基因及其检测引物和应用；专利号：201710618263.2（第一发明人：饶秋）；

（4）专利名称：一种Xp11.2 的新易位伴侣FUBP1 及其检测引物和应用；专利号：201710619782.0（第一发明人：饶秋）；

（5）专利名称：一种MATR3-TFE3 融合基因及其检测引物和应用；专利号：

201710458099.3（第二发明人：饶秋）